Advaxis, Inc. (ADXS) EPS Estimated At $-0.41 on June, 5

May 17, 2018 - By Tina Gentry

Advaxis, Inc. (NASDAQ:ADXS) Corporate Logo
Big Money Sentiment decreased to 1.12 in Q4 2017. It has change of 0.11, from 2017Q3’s 1.23. The ratio is negative due to Advaxis, Inc. positioning: 17 sold and 17 reduced. 16 funds took holdings and 22 increased holdings. Investors holded 16.94 million in 2017Q3 but now own 15.17 million shares or 10.45% less.
California Public Employees Retirement Systems invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Jpmorgan Chase Company invested 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS). Interest Gru Inc has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Fmr Ltd Company stated it has 542,230 shs. Royal Comml Bank Of Canada owns 184 shs. Voya Management Limited Liability stated it has 0% in Advaxis, Inc. (NASDAQ:ADXS). Susquehanna Interest Grp Incorporated Ltd Liability Partnership has invested 0% of its capital in Advaxis, Inc. (NASDAQ:ADXS). Barclays Public Limited holds 26 shs or 0% of its capital. New York-based Bnp Paribas Arbitrage Sa has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Schwab Charles Mgmt Inc holds 0% in Advaxis, Inc. (NASDAQ:ADXS) or 144,036 shs. Moreover, Weiss Multi has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 30,000 shs. 75,876 were accumulated by Cutler Capital Mgmt Lc. Jefferies Group Llc accumulated 442,900 shs or 0.01% of the stock. Moreover, D E Shaw And has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 424,404 shs. Geode Mgmt Ltd Liability accumulated 0% or 282,545 shs.

Advaxis, Inc. had 3 insider sales and 0 buys since December 29, 2017. This’s net activity of $20,259. On Thursday, March 29 a trade for 2,193 shs valued at $3,553 was made by PETIT ROBERT. On Friday, December 29 Bonstein Sara also sold $16,612 worth of Advaxis, Inc. (NASDAQ:ADXS).

On June, 5 WallStreet anticipated Advaxis, Inc. (NASDAQ:ADXS)’s earnings release, according to RTT. Analysts forecast $-0.41 earnings per share, which is $0.10 up or 19.61 % from 2017’s $-0.51 earnings per share. -16.33 % EPS growth is what Wall Street’s forecasts after $-0.49 reported EPS previous quarter. ADXS is hitting $1.87 during the last trading session, after decreased 6.50%.Advaxis, Inc. has volume of 753,197 shares. Since May 17, 2017 ADXS has declined 77.70% and is downtrending. ADXS underperformed the S&P 500 by 89.25%.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Total analysts of 2 have positions in Advaxis (NASDAQ:ADXS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 27, 2017 according to StockzIntelligence Inc Advaxis has 3 analyst reports. On Wednesday, March 14 the stock has “Buy” rating by H.C. Wainwright. On Wednesday, December 27 the rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, March 13 the rating was maintained by Cantor Fitzgerald with “Overweight”.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.The firm is worth $97.83 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer.Currently it has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Another two news for Advaxis, Inc. (NASDAQ:ADXS) were recently brought out by: Nasdaq.com on May 14, 2018 with title “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …”. The other Streetinsider.com‘s article was titled “Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy” and brought out on May 11, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: